What are the signs of female infertility, and when should I get tested?
Female infertility can look very different from one person to the next, and in many cases, it has no obvious signs at all. Some women notice symptoms that may warrant earlier evaluation: irregular or absent menstrual periods, cycles that are unusually heavy or painful, a history of pelvic infections or sexually transmitted diseases, or recurrent pregnancy loss. These can all be signals that your reproductive system needs closer examination.
But many causes of infertility are entirely silent. A woman may have regular periods, feel completely healthy, and still have underlying factors, such as low ovarian reserve, blocked fallopian tubes, or subtle hormonal imbalances, that are making conception more difficult. This is why waiting for a symptom before seeking evaluation is not always the right approach.
Clinically, infertility is defined as the inability to conceive after 12 months of regular, unprotected intercourse, or 6 months for women over 35, given the more rapid decline in ovarian reserve with age. However, a woman doesn’t have to meet that definition to benefit from testing. If you have a known risk factor, such as a prior diagnosis of PCOS, endometriosis, or a history of uterine surgery, or if you simply want to understand your fertility before you start trying, an early evaluation is always a reasonable and proactive choice.
Possible Causes of Female Infertility
Fertility testing is designed to identify the conditions and factors that may be contributing to difficulty conceiving. Common causes of female infertility include:
- Polycystic ovary syndrome (PCOS): A hormonal disorder that affects ovulation and is one of the most common causes of female infertility. Women with PCOS may have irregular cycles, elevated androgens, and multiple small follicles on the ovaries.
- Endometriosis: A condition in which tissue similar to the uterine lining grows outside the uterus, causing inflammation, adhesions, and potential damage to the fallopian tubes and ovaries.
- Uterine fibroids or polyps: Noncancerous growths in or on the uterus that can interfere with implantation or block the fallopian tubes, depending on their size and location.
- Blocked fallopian tubes (tubal factor infertility): Damage or blockage in one or both fallopian tubes — often caused by prior infection, endometriosis, or surgery — that prevents sperm from reaching the egg or a fertilized egg from reaching the uterus.
- Primary ovarian insufficiency (POI): A condition in which the ovaries stop functioning normally before age 40, resulting in reduced egg supply and irregular or absent periods. Previously referred to as premature ovarian failure.
- Hormonal imbalances: Disruptions to the reproductive hormone axis, including elevated prolactin, thyroid dysfunction, or abnormal FSH and LH levels, can interfere with ovulation and overall cycle health.
- Low ovarian reserve: A reduced quantity of eggs remaining in the ovaries, which can affect both the likelihood of natural conception and the response to fertility treatments.
- Irregular or absent ovulation: Ovulatory dysfunction is one of the most common causes of female infertility. Without regular ovulation, conception cannot occur naturally.
- Pelvic adhesions or scarring: Scar tissue within the pelvis, often resulting from prior surgery, infection, or endometriosis, can distort reproductive anatomy and interfere with fertility.
- Genetic or chromosomal conditions: Certain inherited or spontaneous genetic abnormalities can affect ovarian function, egg quality, or the ability to carry a pregnancy to term.
- Recurrent pregnancy loss: Experiencing two or more miscarriages may indicate an underlying uterine, hormonal, chromosomal, or immune-related issue that warrants further investigation.
- Unexplained infertility: In some cases, standard testing does not identify a clear cause despite thorough evaluation. Advanced testing and personalized treatment approaches are still available and often effective.
What is AMH testing, and why does it matter?
Anti-Müllerian Hormone (AMH) testing has become one of the most important tools in female fertility evaluation. AMH is a hormone produced directly by the small follicles in the ovaries, and its level in the bloodstream provides a reliable, real-time estimate of a woman’s ovarian reserve: the quantity of eggs she has remaining.
Unlike some fertility tests that must be timed to a specific point in the menstrual cycle, AMH can be measured on any day, making it a convenient and highly practical test. A single blood draw is all that’s required.
AMH levels are interpreted relative to a woman’s age, because what’s considered “normal” shifts over time as ovarian reserve naturally declines.
- Higher AMH levels: Generally indicate a larger remaining egg supply and a stronger predicted response to ovarian stimulation during fertility treatments such as IVF. Very high AMH may also be associated with PCOS.
- Lower AMH levels: Suggest a diminished ovarian reserve, meaning fewer eggs remain. This can affect natural conception chances and the expected response to fertility medications. It does not mean conception is impossible, but it does provide important context for planning.
It’s important to understand that AMH measures quantity, not quality. Egg quality is influenced by age and other factors, and a woman with a lower AMH may still conceive successfully, particularly if she is younger. Your fertility specialist will always interpret AMH results alongside other markers, including antral follicle count on ultrasound and day 3 FSH levels, to build a complete picture of your ovarian reserve and what it means for your fertility goals.
AMH testing is particularly valuable for women who are considering egg freezing or embryo banking, as it helps predict how the ovaries are likely to respond to stimulation. It is also useful for women with a family history of early menopause or those who have undergone treatments that may have affected ovarian function, such as chemotherapy.
What other female fertility testing is part of an overall evaluation?
AMH testing is an important starting point, but a complete female fertility evaluation typically involves several additional assessments. The specific tests recommended will depend on your age, health history, cycle patterns, and the findings of your initial consultation. Here is an overview of what may be included:
Medical History and Physical Examination
Every fertility evaluation begins with a detailed medical history. Your provider will ask about your menstrual cycle, any prior pregnancies or losses, past surgeries or infections, current medications, and family health history. This conversation helps identify risk factors and guides decisions about which tests are most likely to be informative for your specific situation.
A physical examination, including a pelvic exam, allows your provider to assess reproductive anatomy directly, looking for signs of conditions such as uterine irregularities, ovarian cysts, or tenderness that might suggest endometriosis or pelvic inflammatory disease. Together, history and examination form the essential foundation on which all other testing is built.
Ovulation Assessment
Regular ovulation is essential for natural conception, and confirming that ovulation is occurring — and occurring at the right time — is a key part of any female fertility evaluation. Several methods may be used to assess ovulatory function, including a mid-luteal progesterone blood test (typically drawn around day 21 of a 28-day cycle) to confirm that ovulation has occurred, or basal body temperature charting and ovulation predictor kits to track cycle patterns and the timing of ovulation.
Hormonal Testing
Reproductive hormones work together in a tightly coordinated system, and disruptions at any point can affect ovulation, cycle regularity, and fertility. A hormonal blood panel is a routine part of the female fertility evaluation and typically includes:
- Follicle-Stimulating Hormone (FSH): Measured on day 3 of the cycle, elevated FSH can indicate diminished ovarian reserve or reduced ovarian response.
- Luteinizing Hormone (LH): Works with FSH to trigger ovulation. Abnormal LH patterns may signal PCOS or other ovulatory disorders.
- Estradiol (E2): Also measured on day 3, estradiol provides context for FSH interpretation and helps assess baseline ovarian function.
- Prolactin: Elevated prolactin levels can suppress ovulation and are associated with irregular or absent periods. High prolactin may indicate a benign pituitary growth called a prolactinoma.
- Thyroid-Stimulating Hormone (TSH): Both hypothyroidism and hyperthyroidism can disrupt menstrual cycles and interfere with conception. Thyroid function is routinely screened as part of a fertility workup.
- Androgens (e.g., testosterone, DHEA-S): Elevated androgen levels may suggest PCOS or adrenal dysfunction, both of which can affect ovulation.
Ovarian Reserve Testing
Ovarian reserve refers to the quantity and, to some extent, the quality of a woman’s remaining egg supply. It is one of the most important factors in predicting both natural fertility and the likelihood of success with fertility treatments.
Ovarian reserve is evaluated through a combination of tests that give your fertility specialist a comprehensive view and help inform decisions about treatment timing, medication protocols, and whether fertility preservation may be worth considering.
Hysterosalpingography (HSG)
A hysterosalpingogram (HSG) is an X-ray procedure used to evaluate the interior of the uterus and the patency, or openness, of the fallopian tubes. During the procedure, a small amount of contrast dye is introduced through the cervix into the uterine cavity. X-ray images are taken as the dye flows through the uterus and into the fallopian tubes. If the tubes are open, the dye will spill freely into the pelvis; if a blockage is present, it will show up clearly on imaging. The HSG can also reveal abnormalities within the uterine cavity, such as fibroids, polyps, or structural irregularities. The procedure typically takes about 30 minutes and is performed on an outpatient basis.
Transvaginal Ultrasound Testing
Transvaginal ultrasound is a core diagnostic tool in fertility evaluation. It uses a small, smooth probe inserted into the vagina to produce high-resolution images of the uterus, ovaries, and surrounding structures, providing far greater detail than abdominal ultrasound for reproductive assessment.
Laparoscopy
Laparoscopy is a minimally invasive surgical procedure that allows a fertility specialist to directly visualize the pelvic organs, including the uterus, fallopian tubes, and ovaries, using a thin, lighted camera inserted through a small incision near the navel. It is typically reserved for cases where a structural cause of infertility is suspected but cannot be fully evaluated through imaging alone. While not part of every fertility evaluation, laparoscopy can be a decisive diagnostic step for women with persistent unexplained infertility or a clinical history that raises concern for hidden pelvic pathology.
Genetic Testing
Genetic testing may be recommended as part of a female fertility evaluation in certain clinical situations. Carrier screening tests whether a woman carries gene variants for inherited conditions — such as cystic fibrosis, spinal muscular atrophy, or fragile X syndrome — that could be passed to a child. Additional genetic evaluation may be recommended for women with primary ovarian insufficiency, recurrent pregnancy loss, or for those whose IVF embryos have repeatedly failed to implant or have resulted in miscarriage.
Saline Infusion Sonogram (SIS)
A saline infusion sonogram (SIS), also called a sonohysterogram, is a specialized ultrasound procedure used to evaluate the interior of the uterine cavity in detail. During the procedure, a small amount of sterile saline is gently introduced into the uterus through the cervix, temporarily expanding the cavity and allowing the ultrasound to produce clearer images of the uterine lining and any structures within it. When results suggest an abnormality requiring treatment, hysteroscopic surgery may be recommended as a next step.
